Manisha Pai
Public Communications Contact chez VERTEX PHARMACEUTICALS INCORPORATED
Profil
Manisha Pai is currently working as an Executive Director-Investor Relations at Vertex Pharmaceuticals, Inc. Prior to this, she worked as Head-Public Relations at Millennium Pharmaceuticals, Inc. from 2008 to 2013, and then as Head-Public Relations at Pharmacyclics LLC from 2013 to 2014.
From 2014 to 2015, she worked as Head-IR & Corporate Communications at Epizyme, Inc. and from 2015 to 2017, she worked as Head-IR & Corporate Communications at bluebird bio, Inc. She is also a former Vice President-Investor Relations & Communications at Magenta Therapeutics, Inc. Ms. Pai completed her undergraduate degree from Amherst College.
Postes actifs de Manisha Pai
| Sociétés | Poste | Début |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Public Communications Contact | - |
Anciens postes connus de Manisha Pai
| Sociétés | Poste | Fin |
|---|---|---|
| BLUEBIRD BIO, INC. | Investor Relations Contact | 01/10/2017 |
| EPIZYME, INC. | Investor Relations Contact | 01/04/2015 |
| PHARMACYCLICS, INC. | Corporate Officer/Principal | 01/01/2014 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/07/2013 |
| MAGENTA THERAPEUTICS | Investor Relations Contact | - |
Formation de Manisha Pai
| Amherst College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
